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Abstract Previous studies indicated that the increase in
protein kinase C (PKC)-mediated myoﬁlament protein
phosphorylation observed in failing myocardium might be
detrimentalforcontractilefunction.Thisstudywasdesigned
to reveal and compare the effects of PKCa- and PKCe-
mediated phosphorylation on myoﬁlament function in
human myocardium. Isometric force was measured at dif-
ferent [Ca
2?] in single permeabilized cardiomyocytes from
failing human left ventricular tissue. Activated PKCa and
PKCe equally reduced Ca
2? sensitivity in failing cardio-
myocytes (DpCa50 = 0.08 ± 0.01). Both PKC isoforms
increased phosphorylation of troponin I- (cTnI) and myosin
binding protein C (cMyBP-C) in failing cardiomyocytes.
Subsequent incubation of failing cardiomyocytes with the
catalytic subunit of protein kinase A (PKA) resulted in a
further reduction in Ca
2? sensitivity, indicating that the
effects of both PKC isoforms were not caused by cross-
phosphorylation of PKA sites. Both isozymes showed no
effects on maximal force and only PKCa resulted in a
modest signiﬁcant reduction in passive force. Effects of
PKCa were only minor in donor cardiomyocytes, presum-
ably because of already saturated cTnI and cMyBP-C
phosphorylationlevels.Donortissuecouldthereforebeused
asatooltorevealthe functionaleffectsoftroponinT(cTnT)
phosphorylation by PKCa. Massive dephosphorylation of
cTnT with alkaline phosphatase increased Ca
2? sensitivity.
Subsequently, PKCa treatment of donor cardiomyocytes
reduced Ca
2? sensitivity (DpCa50 = 0.08 ± 0.02) and
solely increased phosphorylation of cTnT, but did not affect
maximal and passive force. PKCa- and PKCe-mediated
phosphorylation of cMyBP-C and cTnI as well as cTnT
decrease myoﬁlament Ca
2? sensitivity and may thereby
reduce contractility and enhance relaxation of human
myocardium.
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Introduction
The protein kinase C (PKC) family consists of a number of
different isozymes with different substrate speciﬁcities [16].
In the failing human heart PKC activity and the expression
of the Ca
2? dependent isoform PKCa are increased [6].
PKCa has been shown to play an important role in the
development of cardiac hypertrophy and heart failure [7, 12,
13]. PKCa directly phosphorylates regulatory myoﬁlament
proteins such as cardiac troponin I (cTnI) and cardiac tro-
ponin T (cTnT) [17]. PKCa also phosphorylates protein
phosphatase inhibitor 1, which alters the activity of protein
phosphatase 1 [7, 31]. PKCe is another (Ca
2? independent)
PKC isoform, which translocates upon activation to the
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DOI 10.1007/s00395-009-0053-zmyoﬁlaments (and the sarcolemma) [10, 15, 16]. Several
myoﬁlament regulatory proteins [myosin binding protein C
(cMyBP-C), cTnT, cTnI] serve as targets for PKCe [24, 40].
Moreover, transgenic mice overexpressing constitutively
active PKCe slowly develop dilated cardiomyopathy with
failure [11].
Studies in rodent myocardium indicated that cTnT and
cTnI phosphorylation inﬂuence Ca
2? sensitivity and were
involved in the PKC-mediated depression of the maximal
force generating capacity [8, 18, 32, 33]. Using an in vitro
motility assay, an association was observed between the
increased PKC expression in failing human hearts and a
reduction of the force exerted on thin ﬁlaments [29].
Moreover, a recent study using two different animal models
of congestive heart failure, in which PKCa expression and
activation was considerably increased, provided evidence
that augmented PKCa-induced myoﬁlament protein phos-
phorylation contributes to myoﬁlament dysfunction by a
reduction of maximum force and of Ca
2? sensitivity [2].
The expression of the different PKC isoforms, with
different substrate speciﬁcity, varies between rodents and
humans and with different disease states [1, 19]. This may
affect the basal phosphorylation status of the myocardium
and thus inﬂuence the effects of the kinases on Ca
2? sen-
sitivity and force development per se. Speciﬁc information
on the impact of the different PKC isoforms on contractile
function in human myocardium is lacking. Therefore, we
investigated the impact of PKCa and PKCe in human tissue
from donor and end-stage failing hearts obtained during
transplant surgery.
Materials and methods
Human ventricular tissue
Left ventricular (LV) transmural tissue samples were
obtained during heart transplantation surgery from ten
patients with end-stage dilated cardiomyopathy (NYHA
IV) and four non-failing donor hearts (Table 1). The tissue
was collected in cardioplegic solution and stored in liquid
nitrogen. Samples were obtained after informed consent
and with approval of the local Ethical Committee (St
Vincents’ Hospital Human Research Ethics Committee:
File number: H03/118; Title: Molecular Analysis of
Human heart Failure). The investigation conforms with
the principles outlined in the Declaration of Helsinki
(Cardiovascular Research 1997;35:2–4).
Force measurements
Cardiomyocytes were mechanically isolated, Triton X-100
permeabilized and mounted in the experimental set-up at a
sarcomere length of 2.2 lm. Force measurements and
maximal rate of force redevelopment measurements were
performed as described previously [28, 35–37].
Brieﬂy, a single cardiomyocyte was mounted between a
force transducer and piezoelectric motor. After transferring
the cardiomyocyte from relaxing solution (5.89 mM
Na2ATP, 6.48 mM MgCl2, 40.76 mM propionic acid
(Kprop), 100 mM Bis-2-aminoethanesulfonic acid (BES),
7.0 mM ethylene glycol tetra acetic acid (EGTA), 14.5 mM
phosphocreatine disodium salt (CrP), pH 7.10 at 15C, pCa
9) to activating solution (5.97 mM Na2ATP, 6.28 mM
MgCl2,40.64 mMKprop,100 mMBES,7.0 mMCaEGTA,
14.5 mM CrP, pH 7.10 at 15C, pCa 4.5), isometric force
was measured. After reaching steady force, the cardiomyo-
cyte was 20% reduced in length within 2 ms and restretched
after 30 ms (slack test). During this slack test, force ﬁrst
droppedtozeroandaftertherestretchquicklyredevelopedto
theoriginalsteadystatelevel.Asingleexponentialwasﬁtted
to estimate the rate constant of force redevelopment at
maximal activation (Ktr-max). Calcium sensitivity (pCa50)
was determined by measuring force in activating solutions
withsubmaximal[Ca
2?](pCavaluesrangedfrom5.0to6.0)
obtainedbyappropriatemixingoftheactivatingandrelaxing
solutions. The initial control force at maximal [Ca
2?] (i.e.,
pCa 4.5) was used to calculate the maximal force per cross-
sectional area. The force values at submaximal [Ca
2?] were
normalized to the interpolated control values [38].
After the initial force-pCa series, the myocyte was
incubated for 60 min at 20Ci naC a
2?-containing solution
(pCa 5.9) containing 6 mM dithiothreitol (DTT), 1 lM
PMA (phorbol 12-myristate 13-acetate; Sigma), 50 nM
calyculin A (calA, Sigma) without kinase (time control),
Table 1 Characteristics from donors and patients
Sex Age LVEF (%) Medication
Donor 1 Female 24 – –
Donor 2 Male 13 – –
Donor 3 Male 21 – –
Donor 4 Female 38 – –
Patient 1 Female 41 – ACEI, Diu
Patient 2 Female 45 8 ACEI, Diu, b
Patient 3 Male 65 – ACEI,Diu
Patient 4 Male 61 12 ACEI, Amio, Diu, b
Patient 5 Male 55 15 ACEI, Diu
Patient 6 Male 56 15 ACEI, Diu, b
Patient 7 Male 56 20 ACEI,Diu,b
Patient 8 Male 27 – ATII, Diu
Patient 9 Female 23 15 ACEI, Diu, b
Patient 10 Female 65 14 ACEI, Diu
LVEF left ventricular ejection fraction, ACEI angiotensin-converting-
enzyme inhibitors, ATII angiotensin II receptor antagonist, Amio
amiodarone, Diu diuretics, b beta-blocker
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123with 10 lg/mL human recombinant PKCa (Sigma P1782;
batch 93K0330) or 10 lg/mL human recombinant PKCe
(Sigma P1164; batch 060K1890). CalA was added to the
incubation buffer to prevent protein dephosphorylation
during incubation. The concentrations of the active PKC
isoforms were saturating as no further effect on cardio-
myocyte function were seen when the concentration was
doubled. A separate group of failing myocytes was incu-
bated for 40 min at 20C in relaxing solution (see above)
containing 6 mM DTT and 100 U/mL of the catalytic
subunit of protein kinase A (PKA, Sigma P2645; batch
35H9522). After the incubation the force-pCa series was
repeated. A third force-pCa series was performed to study
sequential effects, i.e., PKC isoforms after PKA or visa
versa.
The effect of PKCa was also investigated upon pre-
treatment of failing and donor cardiomyocytes with alka-
line phosphatase (AP, calf intestinal, New England
Biolabs; 2,000 U/mL) in relaxing solution (pCa 9) con-
taining 6 mM DTT and 50 lL/mL protease inhibitor
cocktail (PIC, Sigma, P8340) for 60 min at 20C. All force
measurements were performed at 15C.
Protein analysis
Endogenous protein phosphorylation
To preserve the endogenous phosphorylation status, frozen
tissue samples (*1 mg dry weight) were homogenized in
liquid nitrogen and resuspended in 1 mL cold (-20C)
10% trichloroacetic acid solution (TCA; dissolved in ace-
tone containing 0.1% (w/v) DTT) [27]. Tissue homo-
genates were kept for 1 h at -80C and slowly heated to
room temperature by stepwise increments in temperature as
follows: 20 min at -20C, 20 min at 4C and 20 min at
room temperature (20 ± 2C). The homogenates were
thoroughly mixed on a vortex between all steps. Thereafter,
the tissue homogenates were centrifuged at 12,000g for
15 min and tissue pellets were washed with 1 mL of 0.2%
(w/v) DTT-acetone solution and shaken for 5 min at room
temperature. Centrifugation, washing and shaking was
repeated three times. Thereafter tissue pellets were freeze-
dried and homogenized in 1D-sample buffer containing
15% glycerol, 62.5 mM Tris (pH 6.8), 1% (w/v) SDS and
2% (w/v) DTT (ﬁnal concentration 2.5 lg dry weight/lL).
To determine basal phosphorylation status of myoﬁlament
proteins, myocardial samples (TCA treated 20 lg/lane)
were separated on gradient gels (Criterion Tris–HCl 4–15%
gel, BioRad) and stained with Pro-Q diamond phospho-
protein gel stain (Pro-Q; Molecular Probes) in conjunction
with SYPRO Ruby staining (Molecular Probes) of the gels
[43]. The phosphorylation signals for myoﬁlament proteins
were normalized to the intensities of the SYPRO Ruby-
stained myosin binding protein C (cMyBP-C) bands. All
signals were quantiﬁed using the luminescent image ana-
lyzer LAS-3000 (Fuji Science Imaging Systems) and Aida
image analyzer software (Isotopenmebgera ¨te GmbH,
Staubenhardt, Germany).
Alterations in myoﬁlament protein phosphorylation
To investigate the effect of the PKC isoforms as well as of
PKA and AP on myoﬁlament protein phosphorylation
600 lg (dry weight) of tissue was treated in with Triton
X-100 (0.5%) in relaxing solution (pCa 9) containing PIC
(5 lL/mL), phosphatase inhibitor cocktail (PhIC2, Sigma,
P5726, 5 lL/mL) and calA (50 nM) for 5 min at room
temperature, washed twice with relaxing solution without
Triton X-100 and subsequently incubated for 60 min (or
40 min for PKA) at 20C in 100 lL of (1) relaxing solution
containing PIC (50 lL/mL), PhIC2 (50 lL/mL), calA (50
nM) and DTT (6 mM)(=control incubation); (2) activating
solution (pCa 5.9) containing PIC (50 lL/mL), PhIC2
(50 lL/mL), calA (50 nM), DTT (6 mM), PMA (1 lM)
and PKCa (10 lg/mL) or (3) PKCe (10 lg/mL); (4)
relaxing solution containing PIC (50 lL/mL), PhIC2
(50 lL/mL), calA (50 nM), DTT (6 mML) and PKA (100
U/mL); (5) relaxing solution containing PIC (50 lL/mL),
DTT (6 mM) and AP (2,000 U/mL). Part of the tissue
treated with AP was washed and subsequently incubated
with PKCa (see incubation no. 2). Subsequently, tissue was
treated with TCA and analyzed using ProQ-stained gradi-
ent gels as described above.
To investigate the effect of PKCa phosphorylation of
titin, tissue samples with a ﬁnal concentration of *10 lg/lL
dry weight were homogenized in 100-150 lL sample
buffer consisting of 0.55 M Tris HCL, 0.55 M EDTA, 10%
glycerol, 1% b-mercaptoethanol, 20% (w/v) SDS, 8 lL/mL
leupeptin (Peptin-institute, Japan), 10 lL/mL PhIC1
(Sigma, P2850) and PhIC2, pH6.8. Myocardial samples
(*100 lg/lane) were separated on agarose strengthened
2% sodium dodecyl sulfate-polyacrylamide gels and
stained with Pro-Q diamond phosphoprotein gel stain in
conjunction with Sypro Ruby staining [5]. Staining and
analysis as described above.
Data analysis
Force-pCa relations were ﬁt to the Hill equation as
described previously [37]. Values are given as mean ±
SEM of n experiments. Cardiomyocyte force values for
donor and failing samples were compared using an
unpaired Student t test. Effects of incubations without or
with PKCa, PKCe, PKA or AP were tested with paired
Student t test. Repeated measures ANOVA followed by a
Bonferroni post hoc test was used when studying the
Basic Res Cardiol (2010) 105:289–300 291
123effects of sequential incubations with the PKC isoforms,
PKA or AP. P\0.05 was considered signiﬁcant.
Results
PKCa and PKCe phosphorylation of cTnI and cMyBP-C
decrease Ca
2? sensitivity in failing myocardium
Direct incubation of the cardiomyocytes from failing hearts
with saturating amounts of PKCa (n = 14 cardiomyocytes)
and PKCe (n = 7 cardiomyocytes) resulted in a decrease in
Ca
2? sensitivity (pCa50) (Fig. 1a, b). Both PKC isoforms
had no effect on maximal force (Fmax). Passive force (Fpas)
was reduced after PKCa treatment, whereas PKCe had no
signiﬁcant effect on Fpas (Table 2a). Fmax, Fpas and pCa50
did not change in the absence of kinases (time control;
n = 6 failing cardiomyocytes), while the steepness of the
force-pCa relationship (nH) slightly decreased (Table 2a).
Figure 1c shows a phosphoprotein (ProQ) stained 1D
gel of failing tissue samples treated with PKCa and PKCe,
at concentrations of 10 and 50 lg/mL. The phosphorylated
active forms of PKCa and PKCe became apparent in the
incubations with 50 lg/mL kinase. Gels were subsequently
stained with SYPRO Ruby to correct for differences in
protein loading. The phosphorylation levels with 50 lg/mL
kinase were similar to the incubations with 10 lg/mL
kinase, indicating that the standard concentrations of
10 lg/mL kinase yielded the maximum obtainable phos-
phorylation level. To further investigate if PKCa and PKCe
are able to phosphorylate cTn, recombinant human tropo-
nin complex [43] was incubated with both isoforms. The
results on the recombinant, non-phosphorylated troponin
complex clearly indicate that PKCa and PKCe both phos-
phorylate cTnT and cTnI and that the efﬁcacy of PKCe was
less than that of PKCa (Fig. 1d).
Figure 1e shows that PKCa (n = 5) and PKCe (n = 2)
caused pronounced (2- to 3-fold) increases in cTnI and
cMyBP-C phosphorylation in failing myocardium (relative
to the control incubation without kinase which was set to
1). The relative increase in cMyBP-C phosphorylation by
PKCe (3.4 ± 0.5) was somewhat higher to that observed
with PKCa (2.1 ± 0.4), while phosphorylation of cTnI
with PKCe (1.6 ± 0.1) was lower compared with PKCa
(2.9 ± 0.6). A minor increase in desmin phosphorylation
was observed with both isoforms, while only PKCa slightly
increased cTnT phosphorylation. No effects were observed
on phosphorylation of myosin light chain 2 (MLC-2). As
PKCa lowered passive force, the effect of PKCa incubation
on the phosphorylation of cardiac titin was analyzed in
failing (n = 5) and donor (n = 6) tissue. Incubation with
PKCa did not result in a signiﬁcant change in titin phos-
phorylation in both donor and failing tissue (Fig. 2a, b).
To address the origin of the shift in Ca
2? sensitivity in
failing hearts, cells were treated with PKA after incubation
with PKCa and e. This resulted in a further reduction in
Ca
2? sensitivity (Fig. 3a, b), without any signiﬁcant effect
on Fmax and Fpas (Table 2a). Reversal of the PKA and
PKCa/e sequences yielded similar reductions in Ca
2?
sensitivity for PKA and PKCa and e, indicating that the
effects of PKCa and e on Ca
2? sensitivity were indepen-
dent of that of PKA (Fig. 3c, d; Table 2a).
On average, Ktr-max [tension redevelopment rate (s
-1)
at maximal Ca
2? concentration] was signiﬁcantly increased
after PKCa, PKCe and PKA incubation in failing cardio-
myocytes (Table 2a). However, it must be noted that the
change in Ktr-max in failing cells upon kinase treatments
did not signiﬁcantly differ from the increase observed in
the (time) control incubations (Table 2a). These results
suggest that the kinases and phosphatase used have little,
if any, effect on the kinetics of force redevelopment at
saturating calcium concentration.
PKCa decreases Ca
2? sensitivity via cTnT
phosphorylation
As observed in a previous study [14, 36], analysis of
baseline endogenous myoﬁlament protein phosphorylation
revealed signiﬁcantly higher cMyBP-C and cTnI phos-
phorylation in donor samples in comparison to failing
samples, while no signiﬁcant differences in phosphoryla-
tion were observed for desmin, cTnT and MLC-2 (Fig. 4a).
Fmax and Fpas did not signiﬁcantly differ between failing
(n = 56; Fmax 31.7 ± 1.5 kN/m
2 and Fpas 1.6 ± 0.1 kN/
m
2) and donor (n = 20; Fmax 33.8 ± 3.0 kN/m
2 and Fpas
1.8 ± 0.2 kN/m
2) cardiomyocytes, while Ca
2? sensitivity
of the myoﬁlaments was signiﬁcantly higher in failing
(5.66 ± 0.01; n = 54) compared to donor (5.50 ± 0.01;
n = 20) myocardium. In addition the steepness of the pCa-
force relationship (nH) was slightly lower in failing
(3.48 ± 0.09; n = 54) compared to donor (3.85 ± 0.19;
n = 20) cells (P\0.05). Ktr-max was slightly, though not
signiﬁcantly, higher in failing (0.84 ± 0.02 s
-1; n = 56)
than in donor (0.77 ± 0.03 s
-1; n = 20) cells. Previous
analysis using two-dimensional gel electrophoresis
revealed that endogenous cTnT phosphorylation is high
(*63%), both in donor and failing myocardium [36]. To
uncover functional effects of PKCa-mediated cTnT phos-
phorylation in human tissue, PKCa incubations were
repeated after pretreatment of failing and donor cardio-
myocytes with AP. AP signiﬁcantly reduced cTnT phos-
phorylation to 15% of its original level in donor and to 17%
in failing myocardium without dephosphorylation of cTnI
(Fig. 5a, b). AP treatment also signiﬁcantly reduced
phosphorylation of cMyBP-C (*30%) in donor myocar-
dium, and of desmin (*30%) in failing tissue. Subsequent
292 Basic Res Cardiol (2010) 105:289–300
123phosphorylation by PKCa of samples dephosphorylated by
AP resulted in signiﬁcant increases in cTnT phosphoryla-
tion in failing (170%) and in donor tissue (95%). In addi-
tion, PKCa signiﬁcantly increased phosphorylation of
cMyBP-C (*23%), desmin (*113%), cTnI (*160%) and
MLC-2 (*80%) in failing tissue, while in AP pre-treated
donor tissue, cTnT was the only protein phosphorylated by
PKCa (Fig. 5c).
After the massive dephosphorylation of cTnT, the effects
of PKCa on cardiomyocyte function were studied. AP
treatment resulted in an increase in Ca
2? sensitivity, which
was similar in failing and donor tissue (Fig. 6a, b;
DpCa50 = 0.09). Subsequent treatment with PKCa resulted
in a decline in Ca
2? sensitivity to a level (pCa50 after
AP-PKCa: 5.60 ± 0.01 and 5.51 ± 0.02 in failing and
donor, respectively) similar to that observed after PKCa
treatment, without AP pretreatment (Table 2b). The steep-
ness of the force-pCa relation decreased upon AP in failing
and donor cells and remained low after PKCa (Table 2b). A
similar decline in steepness of the Ca
2? sensitivity curve
was observed in the time control experiments in the absence
of kinase or phosphatase. AP treatment resulted in a small
but signiﬁcant increase in Fmax in failing cells (Fig. 6c). In
donor cells (Fig. 6d) no effect on Fmax was observed. PKCa
applied after AP treatment did not affect Fmax in both
groups. AP also caused a signiﬁcant increase in Fpas in both
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123failing and donor cells (Fig. 6e, f), but subsequent PKCa
treatment failed to restore the original levels.
Discussion
This study shows that PKC-mediated phosphorylation of
cMyBP-C and cTnI as well as of cTnT cause a reduction of
Ca
2? sensitivity of force development in human myocar-
dium. No effects on maximal force generating capacity of
the myoﬁlaments were observed, neither upon direct PKC
treatment nor following phosphatase pretreatment. On the
basis of these data we propose that increased PKC activity
in failing myocardium may depress systolic function of the
heart as for the same intracellular Ca
2? concentration, the
myoﬁlament force generation and thereby developed
pressure will be reduced. On the other hand, the reduced
myoﬁlament Ca
2? sensitivity may help myocardial relax-
ation as Ca
2? concentrations are increased in failing hearts
[3, 9].
PKCa and PKCe phosphorylation of cTnI and cMyBP-C
decrease Ca
2? sensitivity in failing myocardium
Direct incubation of the cardiomyocytes from failing hearts
with saturating amounts of active PKCa and PKCe resulted
in a decrease in Ca
2? sensitivity (Fig. 1). PKCa and PKCe
incubations of failing tissue resulted in increased phos-
phorylation of cMyBP-C and cTnI. PKCa incubation
resulted in higher phosphorylation of cTnI and PKCe in
Table 2 Overview of the force measurements with PKCa, PKCe and PKA incubations (a) and AP and PKCa incubations (b)
Incubation Cardiomyocyte measurements
Fmax Fpas pCa50 nH Ktr-max (s
-1)
(a)
PKCa 7 failing hearts; 14 myocytes
Before 28.2 ± 2.4 1.5 ± 0.2 5.67 ± 0.03 3.43 ± 0.18 0.69 ± 0.03
After 28.6 ± 2.4 1.4 ± 0.2* 5.59 ± 0.03* 3.28 ± 0.24 0.81 ± 0.04*
PKCe 5 failing hearts; 7 myocytes
Before 30.3 ± 3.9 1.6 ± 0.3 5.68 ± 0.03 3.86 ± 0.20 0.60 ± 0.05
After 31.2 ± 3.1 1.4 ± 0.2 5.60 ± 0.02* 3.42 ± 0.13 0.74 ± 0.05*
PKA 7 failing hearts; 14 myocytes
Before 22.8 ± 2.1 1.4 ± 0.2 5.65 ± 0.02 3.34 ± 0.07 0.68 ± 0.02
After 22.9 ± 2.0 1.4 ± 0.1 5.53 ± 0.01* 3.57 ± 0.13* 0.84 ± 0.04*
Control
# 2 failing hearts; 6 myocytes
Before 22.7 ± 2.5 1.5 ± 0.1 5.66 ± 0.03 3.16 ± 0.12 0.64 ± 0.06
After 22.1 ± 2.5 1.3 ± 0.1 5.67 ± 0.03 2.65 ± 0.11* 0.74 ± 0.04
(b)
AP 5 failing hearts; 11 myocytes
Before 35.7 ± 3.6 1.8 ± 0.3 5.64 ± 0.02 3.68 ± 0.11 0.76 ± 0.07
After 38.6 ± 4.5* 2.5 ± 0.3* 5.73 ± 0.03* 2.85 ± 0.13* 0.68 ± 0.04
AP ? PKCa 5 failing hearts; 10 myocytes
Before 35.5 ± 3.8 2.6 ± 0.3 5.73 ± 0.03 2.84 ± 0.14 0.56 ± 0.06
After 35.1 ± 3.9 2.4 ± 0.4 5.60 ± 0.01* 2.99 ± 0.15 0.66 ± 0.09
AP 4 donor hearts; 8 myocytes
Before 34.1 ± 4.5 1.5 ± 0.2 5.48 ± 0.02 4.04 ± 0.19 0.62 ± 0.09
After 34.3 ± 4.9 2.0 ± 0.4* 5.57 ± 0.02* 3.33 ± 0.18* 0.67 ± 0.07
AP ? PKCa 4 donor hearts; 7 myocytes
Before 31.6 ± 4.4 2.2 ± 0.4 5.59 ± 0.02 3.25 ± 0.18 0.57 ± 0.04
After 31.3 ± 4.8 2.0 ± 0.4 5.51 ± 0.02* 3.30 ± 0.15 0.76 ± 0.07*
Fmax, maximal force at maximal calcium concentration in kN/m
2; Fpass, passive force measured in free calcium solution in kN/m
2; nH, steepness
of the force-pCa curves
* P\0.05, before versus after incubation in paired t test
# Time control incubations
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123higher phosphorylation levels of cMyBP-C, indicating iso-
zyme speciﬁc substrate afﬁnity. Although phosphorylation
effects were diverse, the functional consequences of both
PKC isoforms were quite similar.
It has previously been determined that cMyBP-C has
PKC-phosphorylatable residues [24, 40]. However, so far
no data has been published (to our knowledge) that directly
link cMyBP-C phosphorylation with alterations in Ca
2?
sensitivity. Our data suggest involvement of PKC-mediated
cMyBP-C phosphorylation in the reduced Ca
2? sensitivity
observed in failing tissue.
Kobayashi et al. [20] indicated that PKCe was able to
phosphorylate PKA sites on mouse cTnI. Our previous
study also showed that the active catalytic domain of PKC
caused cross-phosphorylation of the PKA sites (Ser23/24)
[35]. We addressed this issue for PKCa- and PKCe-medi-
ated phosphorylation by performing experiments where
incubations of PKCa or PKCe were followed by PKA as
well as by incubations in the reverse order. The results
showed that the shifts in Ca
2? sensitivity in failing myo-
cardium did not depend on the sequence of application of
PKA and PKCa/e. This indicates that the effects of the
PKC isoforms and PKA were independent and that the
PKCa/e-mediated effects were not caused by cross-phos-
phorylation of the PKA sites under our conditions.
Kobayashi et al. [20] used the recombinant mouse cTnI and
an excess of PKCe, therefore it is possible that the cross-
phosphorylation they observed does not occur under more
physiological conditions or that it is more pronounced in
mice than in human cTn.
PKCa decreases Ca
2? sensitivity via cTnT
phosphorylation
Direct incubation of donor cells with PKCa did not alter
Ca
2?sensitivity(Fig. 4b),whichisinlinewithminoreffects
of PKCa on protein phosphorylation of cMyBP-C, desmin,
cTnI, cTnT and MLC2 (Fig. 4c). The absence of functional
effects of PKCa is most likely explained by the relatively
high baseline phosphorylation status of cMyBP-C, cTnI and
cTnTindonormyocardium.BecauseendogenouscMyBP-C
and cTnI phosphorylation levels in donor tissue were high
(Fig. 4a) and no major effects of PKCa on Ca
2? sensitivity
and protein phosphorylation were observed (Fig. 4b, c), the
donor tissue was used asa tool to reveal functionaleffects of
PKCa-mediated phosphorylation of cTnT.
AP treatment resulted in a massive decrease in cTnT
phosphorylation in failing and donor myocardium. Sub-
sequent treatment with PKCa solely increased phosphory-
lation of cTnT in donor myocardium, which made it
possible to identify the role of cTnT upon phosphorylation
by PKCa. Treatment with PKCa following AP treatment
showed a signiﬁcant reduction in Ca
2? sensitivity in both
failing and donor tissue. These results indicate that AP is
able to dephosphorylate sites on cTnT, which are subse-
quently targeted by PKCa and when phosphorylated reduce
Ca
2? sensitivity.
Overall, our results are in agreement with previous
animal studies [17, 24, 40] indicating that functionally
relevant targets of PKCa- and PKCe-mediated Ca
2?
desensitization of the myoﬁlaments are located on cardiac
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AB Fig. 2 Effect of PKCa
incubation on the
phosphorylation of titin in
failing (n = 5) and donor
(n = 6) tissue. Sypro and ProQ
stained agarose strengthened
5% sodium dodecyl sulfate-
polyacrylamide gels of donor
and failing tissue samples
incubated with and without
PKCa. Phosphorylation of
myoﬁlament proteins was
expressed relative to the Sypro
Ruby-stained titin bands to
correct for differences in protein
loading. Incubation with PKCa
did not result in a signiﬁcant
increase of titin phosphorylation
both in donor and failing tissue
(a, b). Kinase versus control
incubation in paired t test
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123troponin. Both cTnI and cTnT contain a number of dif-
ferent PKC-phosphorylatable sites. On the basis of bio-
chemical in vitro studies Ser-42 and Ser-44 and Thr-143
on cTnI [30] and Thr-194, Ser-198, Thr-203 and Thr-284
on cTnT [17, 34] are considered the main sites (phos-
phorylated sites based on human sequence). It has been
proposed that the relative balance of phosphorylation of the
three PKC sites on cTnI is important for the regulation of
its function [32]. Pseudophosphorylation of Ser-42/Ser-44
signiﬁcantly reduced the myoﬁlament response to calcium
and phosphorylation of Thr-143 induced an increase in
sensitivity to calcium [7, 39]. Among the four phosphor-
ylation sites on cTnT, Thr-203 appeared to be the most
important for modulation of cTn function in that it inhi-
bited force as well as its Ca
2? sensitivity [33].
PKCa reduces passive force, but not maximal force
Rodent studies indicate that PKC-mediated phosphorylation
results in a reduction of the maximum force generating
capacity of the cardiomyocytes [8, 26, 32, 33]. A study
using an in vitro motility assay suggested that this might
also be the case in human tissue [2]. However, the present
results did not show depression of force upon PKC treat-
ment and indicate that caution should be exerted when
extrapolating data obtained in rodent studies to force
development in human cardiomyocytes. Cardiac cTnI and
cTnT phosphorylation by PKC may occur at different sites
in different species and may explain the absence of an effect
of PKCa on Fmax in human cardiomyocytes. Only recently,
using mass spectrometry Zabrouskov et al. [42] revealed a
novel phosphorylation site (Ser-76 or Thr-77) in human
cTnI, while no phosphorylation was observed at the sites
mentioned above. A study in mice revealed that the PKCa-
induced reduction in Fmax critically depended on cTnT
phosphorylation at Thr-203 [33]. Future studies should be
performed to reveal which sites are phosphorylated by PKC
in human myocardium. Recently Molna ´r et al. [25] showed
that PKCa contributes to the maintenance of contractile
force in human cardiomyocytes, which is in line with our
Fig. 3 PKCa and e do not
cross-phosphorylate the PKA
sites (Ser23/24). After the ﬁrst
force-pCa series (control, before
incubation) myocytes from
failing hearts were incubated
with PKCa or PKCe and a
second force-pCa series was
measured. Thereafter the
myocytes were incubated with
PKA, which saturates the PKA
sites on cTnI and the third force-
pCa series was measured (a, b).
PKCa-PKA, n = 9; PKCe-
PKA, n = 7. PKCa and PKCe
caused a reduction in Ca
2?
sensitivity and subsequent
incubation with PKA results in a
further reduction of Ca
2?
sensitivity. Reversal of the order
of application of the PKC
isoforms and PKA (c, d)
resulted in similar reductions in
pCa50. PKA–PKCa, n = 8;
PKA–PKCe, n = 6.
#P\0.05,
in repeated measures ANOVA.
*P\0.05, before versus after
kinase treatment in Bonferroni
post hoc test
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123results that PKCa treatment does not negatively affect
maximal force. AP treatment resulted in a small (*5%) but
signiﬁcant increase in Fmax. However, subsequent treatment
with PKCa did not result in a reduction of force develop-
ment. This suggests that AP is able to dephosphorylate at
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Fig. 4 Basal phosphorylation of donor versus failing tissue and the
effect of PKCa phosphorylation on donor tissue. a Endogenous
phosphorylation of myosin binding protein C (cMyBP-C) and
troponin I (cTnI) was signiﬁcantly lower in failing (n = 10)
compared to non-failing donor (n = 4) samples. *P\0.05, donor
versus failing in unpaired t test. b PKCa treatment did not alter force
characteristics of non-failing donor cardiomyocytes. c Average data
using 10 lg/mL of PKCa in samples from donor (n = 4) hearts. In
donor tissue the only signiﬁcant effect was a small (9 ± 3%) increase
in cMyBP-C phosphorylation. *P\0.05, kinase versus control
incubation in paired t test
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mintStick Phosphoprotein marker (Molecular Probes). b Changes in
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123least to some extent one of the contractile proteins deter-
mining Fmax. However, in human tissue the impact is rather
small and the link with PKCa is not evident.
PKCa treatment resulted in a small reduction of Fpas
both in donor and in failing cardiomyocytes, whereas PKCe
had no signiﬁcant effect but did show a similar trend
(Table 2). AP treatment caused a signiﬁcant increase in
Fpas in both failing and donor cells but subsequent PKCa
treatment did not restore the original levels. These results
suggest that the effects of PKCa-mediated phosphorylation
and AP-induced dephosphorylation on stiffness are inde-
pendent, and indicate that at least two distinct phosphory-
lation sites, possibly on titin [4, 22, 41], are involved in
the modulation of passive stiffness of the cardiomyocytes.
To address this issue, the effect of PKCa in titin
phosphorylation after incubation with PKCa was investi-
gated both in donor and failing tissue (Fig. 2). However, no
signiﬁcant effect was observed. This could imply that
phosphorylation of titin is not solely responsible for the
decrease in passive force observed after PKCa. However,
since titin may contain numerous phosphorylation sites
with one or few PKCa dependent sites, it might be that our
method is not sensitive enough to resolve the minor relative
changes in titin phosphorylation as appeared to be the case
for protein kinase G by Kru ¨ger et al. [21].
As high Fpas has been associated with high left ven-
tricular end-diastolic pressure in patients with diastolic
dysfunction [4], the reduction in passive stiffness by
PKCa-mediated phosphorylation might improve diastolic
ﬁlling of the heart.
Fig. 6 The effects of PKCa
after dephosphorylation of cTnT
by alkaline phosphatase (AP) in
failing (n = 5) and donor
(n = 4) tissue. Ca
2? sensitivity
of force was increased after AP
treatment and was subsequently
reduced after PKCa treatment to
the levels observed without AP
pretreatment (a, b). AP
treatment resulted in a minor but
signiﬁcant increase in maximum
force (Fmax) in failing tissue
while in donor tissue no change
was observed (c, d). Subsequent
treatment with PKCa had no
effect on Fmax. Passive force
(Fpas)( e, f) was increased after
AP in failing and donor tissue
and remained elevated after
PKCa treatment. *P\0.05,
before versus after phosphatase/
kinase treatment in Bonferroni
post hoc test
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123Limitations and conclusions
In this study the effects of the kinases and phosphatases on
the phosphorylation levels are represented relative to basal
phosphorylation levels for each protein. Although the
changes in protein phosphorylation levels were relatively
small, the functional changes were signiﬁcant and may be
physiologically relevant.
Since the transition to end-stage heart failure is
accompanied by an increase in PKCa activity [6]i ti s
surprising that the effects of PKCa are observed only in
end-stage failing hearts and become visible in donor hearts
only after dephosphorylation by alkaline phosphatase. It
should be noted, however, that the endogenous phosphor-
ylation levels in the explanted myocardium studied not
necessarily reﬂect the in vivo situation. The lower levels of
cMyBP-C and cTnI phosphorylation observed in end-stage
failing compared to donor myocardium may reﬂect
desensitisation of the b-adrenergic pathway. Moreover, it
has been suggested that high catecholamine levels at the
time of tissue procurement underlies the relative high
levels of cMyBP-C and cTnI phosphorylation levels in
donor myocardium [23]. Future studies in biopsy samples
taken under well-controlled hemodynamic conditions with
parallel measurements of blood catecholamines should be
performed to address this issue. Nevertheless, the data
presented in this study clearly indicate that changes in
expression and activation of PKCa and PKCe in response
to pathophysiological stressors or increased hemodynamic
demands during exercise translate into alterations in con-
tractile function in human myocardium.
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